- Projects & figures
- News & Events
- Managing your project
- About ERC
This 8 March, the ERC celebrates the achievements of grantee Dr Mariana Graña, a determined researcher in a branch of physics where women are still noticeably underrepresented. She reflects on how far women have come in Theoretical Physics and what is still needed to overcome the gender-role stereotypes associated with this appealing but abstract field of science.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
Dr Joaquim Alves Gaspar is a man of the sea. After many years in the Portuguese Navy, he gave up plans to become an admiral in favour of pursuing a PhD in the History of Cartography. This second career led him to receive an ERC Starting Grant, the first awarded in this budding discipline. With his highly multidisciplinary team (he likes to say that, to work with him, one must be a mathematician fluent in Latin), and the experience obtained as a navigator and navigational instructor, Dr Gaspar hopes to understand how and when the first nautical charts were created. The MEDEA-CHART team is the best place in Portugal, and probably in the world, to study the history of nautical cartography, hoping that this work will provide the domain with its rightful recognition within world history.
Severe traffic jams not only have an impact on mobility, they also raise environmental and health issues linked to fuel consumption and air and noise pollution. Prof. Ludovic Leclercq is developing new traffic control models that could tackle road congestion while integrating a green dimension.
For the first time ever, a team of scientists and clinicians led by the EU-funded researcher Mickael Tanter has managed to record the brain activity of a premature new-born baby during resting and during an epileptic seizure. Using a non-invasive ultrasound technology, this world premiere is a real game changer for researchers and the medical profession, offering a massive range of applications in neuroimaging and beyond. It is published today in Science Translational Medicine.
Pour la toute première fois, une équipe de scientifiques et des cliniciens dirigée par le chercheur Mickael Tanter, financé par l'UE, a réussi à enregistrer l'activité cérébrale d'un nouveau-né prématuré en phase de repos et lors d'une crise d'épilepsie. À l'aide d'une technologie d'échographie non invasive, cette première mondiale marque un véritable tournant dans le domaine de la recherche et la pratique médicale. Elle offre par ailleurs une vaste gamme d'applications en neuroimagerie et au-delà. L'étude est publiée aujourd'hui dans Science Translational Medicine.
Our immune system recognizes and fights infections in a constantly changing environment, where new pathogenic threats emerge. At the crossroad between physics and biology, Prof. Aleksandra Walczak investigates the fascinating process that allows the immune system to be always ready to adapt and evolve to face new dangers.
Headscarves, mosques and halal shops — many EU citizens are Muslims, but visible signs of their faith are often viewed with distrust. What some Europeans see as a right to express their identity, others regard as a threat to societal core values. Insights from ERC-funded research into emblematic controversies may help to find a way forward.
The use and misuse of antibiotics has accelerated the emergence of drug-resistant bacterial strains, threatening our ability to treat common diseases. EU-funded research has shed new light on the mechanisms behind these microbial mutations, with implications for our understanding of diseases and resistance to treatment.
Maria Brandão de Vasconcelos, together with her colleague Filipa Matos Baptista, Henrique Veiga-Fernandes (ERC grantee), Diogo Fonseca Pereira and Sílvia Arroz Madeira, founded StemCell2MAX in 2015. The company is a biotechnology start-up, specialised in cell based therapies, including novel solutions to multiply the scarcely available blood stem cells, addressing an enormous demand for research and cancer treatment. StemCell2MAX technology is based on Prof. Veiga-Fernandes's ground-breaking discoveries in hematopoietic stem cell biology.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."